{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:50:54Z","timestamp":1791417054974,"version":"4.3.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":92,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100010166","name":"Xiamen Municipal Bureau of Science and Technology","doi-asserted-by":"publisher","award":["3502Z20244ZD1115"],"award-info":[{"award-number":["3502Z20244ZD1115"]}],"id":[{"id":"10.13039\/100010166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2023J011690"],"award-info":[{"award-number":["2023J011690"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005270","name":"Fujian Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["2022D014"],"award-info":[{"award-number":["2022D014"]}],"id":[{"id":"10.13039\/501100005270","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"DOI":"10.1186\/s12931-026-03793-1","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T23:44:48Z","timestamp":1783467888000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune-related adverse event profiles and survival outcomes in non\u2013small cell lung cancer: a cluster analysis from a long-term real-world study"],"prefix":"10.1186","volume":"27","author":[{"given":"Yijiao","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhisheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"3793_CR1","doi-asserted-by":"crossref","unstructured":"Zhou J, Xu Y, Liu J, Feng L, Yu J, Chen D. Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCAN. Cancer Epidemiol. 2024;93:102693.","DOI":"10.1016\/j.canep.2024.102693"},{"key":"3793_CR2","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"3793_CR3","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/JCO.21.01497","volume":"40","author":"M Reck","year":"2022","unstructured":"Reck M, Remon J, Hellmann MD. First-Line Immunotherapy for Non-Small-Cell Lung Cancer. J Clin Oncol. 2022;40:586\u201397.","journal-title":"J Clin Oncol"},{"key":"3793_CR4","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1001\/jamaoncol.2025.0985","volume":"11","author":"J Heyward","year":"2025","unstructured":"Heyward J, Lesko CR, Murray JC, Mehta HB, Segal JB. Harm-Benefit Balance of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. JAMA Oncol. 2025;11:707\u201316.","journal-title":"JAMA Oncol"},{"key":"3793_CR5","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.jtho.2025.03.033","volume":"20","author":"S Kilickap","year":"2025","unstructured":"Kilickap S, Baramidze A, Sezer A, \u00d6zg\u00fcro\u011flu M, Gumus M, Bondarenko I, Gogishvili M, Nechaeva M, Schenker M, Cicin I, et al. Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1. J Thorac Oncol. 2025;20:941\u201354.","journal-title":"J Thorac Oncol"},{"key":"3793_CR6","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375:1823\u201333.","journal-title":"N Engl J Med"},{"key":"3793_CR7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018;378:158\u201368.","journal-title":"N Engl J Med"},{"key":"3793_CR8","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","volume":"4","author":"DY Wang","year":"2018","unstructured":"Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol. 2018;4:1721\u20138.","journal-title":"JAMA Oncol"},{"key":"3793_CR9","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021;39:4073\u2013126.","journal-title":"J Clin Oncol"},{"key":"3793_CR10","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.cllc.2019.02.006","volume":"20","author":"A Cortellini","year":"2019","unstructured":"Cortellini A, Chiari R, Ricciuti B, Metro G, Perrone F, Tiseo M, Bersanelli M, Bordi P, Santini D, Giusti R, et al. Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. Clin Lung Cancer. 2019;20:237\u2013e247231.","journal-title":"Clin Lung Cancer"},{"key":"3793_CR11","doi-asserted-by":"publisher","first-page":"e2352302","DOI":"10.1001\/jamanetworkopen.2023.52302","volume":"7","author":"S Cook","year":"2024","unstructured":"Cook S, Samuel V, Meyers DE, Stukalin I, Litt I, Sangha R, Morris DG, Heng DYC, Pabani A, Dean M, Navani V. Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors. JAMA Netw Open. 2024;7:e2352302.","journal-title":"JAMA Netw Open"},{"key":"3793_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12916-020-01549-2","volume":"18","author":"X Zhou","year":"2020","unstructured":"Zhou X, Yao Z, Yang H, Liang N, Zhang X, Zhang F. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med. 2020;18:87.","journal-title":"BMC Med"},{"key":"3793_CR13","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.bulcan.2020.04.019","volume":"107","author":"L Bouhlel","year":"2020","unstructured":"Bouhlel L, Doyen J, Chamorey E, Poudenx M, Ilie M, Gal J, Guigay J, Benzaquen J, Marquette CH, Berthet JP, et al. Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab. Bull Cancer. 2020;107:946\u201358.","journal-title":"Bull Cancer"},{"key":"3793_CR14","doi-asserted-by":"publisher","first-page":"100787","DOI":"10.1016\/j.esmoop.2023.100787","volume":"8","author":"V Amoroso","year":"2023","unstructured":"Amoroso V, Gallo F, Alberti A, Paloschi D, Ferrari Bravo W, Esposito A, Cosentini D, Grisanti S, Pedersini R, Petrelli F, Berruti A. Immune-related adverse events as potential surrogates of immune checkpoint inhibitors\u2019 efficacy: a systematic review and meta-analysis of randomized studies. ESMO Open. 2023;8:100787.","journal-title":"ESMO Open"},{"key":"3793_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12885-025-13566-6","volume":"25","author":"X Han","year":"2025","unstructured":"Han X, Chen Y, Xie H, Zhang Y, Cui Y, Guan Y, Nie W, Xie Q, Li J, Wang B, et al. Organ-specific immune-related adverse events and prognosis in cancer patients receiving immune checkpoint inhibitors. BMC Cancer. 2025;25:139.","journal-title":"BMC Cancer"},{"key":"3793_CR16","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12890-025-03742-6","volume":"25","author":"X Wang","year":"2025","unstructured":"Wang X, Fu X, Liu Q, Li J, Ge Y, Zhang J, Wang S, Wang L, Wang D, Sun Y, et al. Impact of irae characteristics on efficacy of consolidative immunotherapy following chemoradiotherapy in locally advanced NSCLC. BMC Pulm Med. 2025;25:283.","journal-title":"BMC Pulm Med"},{"key":"3793_CR17","doi-asserted-by":"publisher","first-page":"1399171","DOI":"10.3389\/fonc.2024.1399171","volume":"14","author":"C Olsson Ladjevardi","year":"2024","unstructured":"Olsson Ladjevardi C, Koliadi A, Ryden V, El-Naggar AI, Digkas E, Valachis A, Ullenhag GJ. Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness. Front Oncol. 2024;14:1399171.","journal-title":"Front Oncol"},{"key":"3793_CR18","unstructured":"SERVICES USDOHAH. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Published: 27 Nov 2017: Available at : https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-5x7.pdf."},{"key":"3793_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"3793_CR20","doi-asserted-by":"crossref","unstructured":"Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, Gerber DE, Hamad L, Hansen E, Johnson DB, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9(6):e002435.","DOI":"10.1136\/jitc-2021-002435"},{"key":"3793_CR21","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714\u201368.","journal-title":"J Clin Oncol"},{"key":"3793_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v025.i01","volume":"25","author":"S L\u00ea","year":"2008","unstructured":"L\u00ea S, Josse J, Husson F. FactoMineR: An R Package for Multivariate Analysis. J Stat Softw. 2008;25:1\u201318.","journal-title":"J Stat Softw"},{"key":"3793_CR23","doi-asserted-by":"publisher","first-page":"175883592312106","DOI":"10.1177\/17588359231210678","volume":"15","author":"Y Chen","year":"2023","unstructured":"Chen Y, Shi Y, Ding H, Feng Y, Zhang T, Liang Y, Wang H, Song X, Chen B, Xia W, et al. Different associations between organ-specific immune-related adverse event and survival in non-small cell lung cancer patients treated with programmed death-1 inhibitors-based combination therapy. Ther Adv Med Oncol. 2023;15:17588359231210678.","journal-title":"Ther Adv Med Oncol"},{"key":"3793_CR24","doi-asserted-by":"publisher","first-page":"1281645","DOI":"10.3389\/fonc.2024.1281645","volume":"14","author":"Y Liang","year":"2024","unstructured":"Liang Y, Xu H, Liu F, Li L, Lin C, Zhang Y, Wang N, Wang L. Immune-related adverse events and their effects on survival outcomes in patients with non-small cell lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Oncol. 2024;14:1281645.","journal-title":"Front Oncol"},{"key":"3793_CR25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/07357907.2021.1994586","volume":"40","author":"T Yamamoto","year":"2022","unstructured":"Yamamoto T, Ito T, Hase T, Ishigami M, Mizuno K, Yamamoto K, Imai N, Ishizu Y, Honda T, Shibata H, et al. Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Cancer Invest. 2022;40:189\u201398.","journal-title":"Cancer Invest"},{"key":"3793_CR26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s00262-024-03871-7","volume":"74","author":"R Pichler","year":"2024","unstructured":"Pichler R, Fritz J, Maier S, Hassler MR, Krauter J, Laukhtina DDA, Gust E, Mori K, Tully K. Target trial emulation to evaluate the effect of immune-related adverse events on outcomes in metastatic urothelial cancer. Cancer Immunol Immunother. 2024;74:30.","journal-title":"Cancer Immunol Immunother"},{"key":"3793_CR27","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4143\/crt.2020.790","volume":"53","author":"SQ Tang","year":"2021","unstructured":"Tang SQ, Tang LL, Mao YP, Li WF, Chen L, Zhang Y, Guo Y, Liu Q, Sun Y, Xu C, Ma J. The Pattern of Time to Onset and Resolution of Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors in Cancer: A Pooled Analysis of 23 Clinical Trials and 8,436 Patients. Cancer Res Treat. 2021;53:339\u201354.","journal-title":"Cancer Res Treat"},{"key":"3793_CR28","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s40487-025-00349-z","volume":"13","author":"A Olsson-Brown","year":"2025","unstructured":"Olsson-Brown A, Jain A, Frazer R, Farrugia D, Carser J, Houghton J, Lewis RD, D\u2019Mello S, Emanuel G. Clinical Management and Outcomes of Immune-Related Adverse Events During Treatment with Immune Checkpoint Inhibitor Therapies in Melanoma and Renal Cell Carcinoma: A UK Real-World Evidence Study. Oncol Ther. 2025;13:649\u201365.","journal-title":"Oncol Ther"},{"key":"3793_CR29","doi-asserted-by":"publisher","first-page":"108555","DOI":"10.1016\/j.lungcan.2025.108555","volume":"204","author":"M Sugai","year":"2025","unstructured":"Sugai M, Amino Y, Fujishima S, Nibuya K, Iso H, Ito M, Tsugitomi R, Ariyasu R, Uchibori K, Yanagitani N, Nishio M. Impact of immune-related adverse event severity on overall survival in patients with advanced NSCLC receiving immune checkpoint inhibitors therapy, with a focus on combination regimens. Lung Cancer. 2025;204:108555.","journal-title":"Lung Cancer"},{"key":"3793_CR30","doi-asserted-by":"crossref","unstructured":"Zablonski KG, Boone JM, Margevicius S, Chakraborty NN, Fu P, Seibert H, Bhatty MA, Mirsky M, Bruno D, Mangla A, et al. Immune-related adverse events, survival outcomes, and next steps in patients with stage III melanoma: real-world experience at a National Cancer Institute-designated Comprehensive Cancer Center. Oncologist. 2025;30(12):oyaf393.","DOI":"10.1093\/oncolo\/oyaf393"},{"key":"3793_CR31","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.21037\/jtd-23-1684","volume":"16","author":"M Xu","year":"2024","unstructured":"Xu M, Xu L, Hao Y, Shao K, Song Z. Clinical characteristics and prognostic implications of immune-related hepatitis in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors: a retrospective study. J Thorac Dis. 2024;16:1900\u201310.","journal-title":"J Thorac Dis"},{"key":"3793_CR32","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41416-020-0882-y","volume":"123","author":"VTF Cheung","year":"2020","unstructured":"Cheung VTF, Gupta T, Olsson-Brown A, Subramanian S, Sasson SC, Heseltine J, Fryer E, Collantes E, Sacco JJ, Pirmohamed M, et al. Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way? Br J Cancer. 2020;123:207\u201315.","journal-title":"Br J Cancer"},{"key":"3793_CR33","doi-asserted-by":"publisher","first-page":"1167975","DOI":"10.3389\/fimmu.2023.1167975","volume":"14","author":"Q Yin","year":"2023","unstructured":"Yin Q, Wu L, Han L, Zheng X, Tong R, Li L, Bai L, Bian Y. Immune-related adverse events of immune checkpoint inhibitors: a review. Front Immunol. 2023;14:1167975.","journal-title":"Front Immunol"},{"key":"3793_CR34","doi-asserted-by":"publisher","first-page":"108","DOI":"10.21037\/tlcr-2026-1-0173","volume":"15","author":"R Tan","year":"2026","unstructured":"Tan R, Qian F, Zhang Y, Cao S, Zhong H. Narrative review of the similarities and differences between immune checkpoint inhibitor- and antibody-drug conjugate-associated pneumonitis. Translational Lung Cancer Res. 2026;15:108\u2013108.","journal-title":"Translational Lung Cancer Res"},{"key":"3793_CR35","doi-asserted-by":"publisher","first-page":"1266850","DOI":"10.3389\/fimmu.2024.1266850","volume":"15","author":"MX Lin","year":"2024","unstructured":"Lin MX, Zang D, Liu CG, Han X, Chen J. Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management. Front Immunol. 2024;15:1266850.","journal-title":"Front Immunol"},{"key":"3793_CR36","doi-asserted-by":"publisher","first-page":"114172","DOI":"10.1016\/j.ejca.2024.114172","volume":"207","author":"RJ Verheijden","year":"2024","unstructured":"Verheijden RJ, Burgers FH, Janssen JC, Putker AE, Veenstra S, Hospers GAP, Aarts MJB, Hehenkamp KW, Doornebosch VLE, Verhaert M, et al. Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma. Eur J Cancer. 2024;207:114172.","journal-title":"Eur J Cancer"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-026-03793-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03793-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03793-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:14:32Z","timestamp":1791414872000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12931-026-03793-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3793"],"URL":"https:\/\/doi.org\/10.1186\/s12931-026-03793-1","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"30 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Ethics Committee of Zhongshan Hospital (Xiamen), Fudan University (Approval No. B2025-026). The requirement for informed consent was waived because of the retrospective design and anonymized data processing.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"388"}}